365 related articles for article (PubMed ID: 26138513)
1. Clinical use of GLP-1 agonists and DPP4 inhibitors.
Tuch BE
Pancreatology; 2016; 16(1):8-9. PubMed ID: 26138513
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
3. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
4. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular effects of incretins in diabetes.
Advani A; Bugyei-Twum A; Connelly KA
Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557
[TBL] [Abstract][Full Text] [Related]
6. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
Paolisso G; Monami M; Marfella R; Rizzo MR; Mannucci E
Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
[TBL] [Abstract][Full Text] [Related]
8. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.
Abbatecola AM; Maggi S; Paolisso G
Drugs Aging; 2008; 25(11):913-25. PubMed ID: 18947259
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
10. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
Unger J
J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
[TBL] [Abstract][Full Text] [Related]
12. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
[TBL] [Abstract][Full Text] [Related]
13. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
15. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
16. Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Hikida K; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Minami M; Shiotani M
J Pharmacol Sci; 2016 Dec; 132(4):255-261. PubMed ID: 27889414
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase-iV inhibitors: fixing type 2 diabetes?
McIntyre HF; Grant P
Br J Hosp Med (Lond); 2007 Nov; 68(11):599-602. PubMed ID: 18087847
[TBL] [Abstract][Full Text] [Related]
18. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Ferrannini E; DeFronzo RA
Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
[TBL] [Abstract][Full Text] [Related]
19. Incretin effect: GLP-1, GIP, DPP4.
Kazafeos K
Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S32-6. PubMed ID: 21864749
[TBL] [Abstract][Full Text] [Related]
20. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]